Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of...
-
Feb 25, 2022
• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response...
-
Feb 17, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment...
-
Feb 7, 2022
New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for...
-
Feb 4, 2022- Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezaparvovec is statistically superior in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy
Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational...
-
Feb 2, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive appointments to strengthen financial and legal leadership during the transformation of the company St. Gallen, Switzerland, 02 February 2022...
-
Jan 19, 2022
First orally administered therapy for the treatment of the two main types of ANCA-associated vasculitis approved in Europe First launches expected in H1 2022 St. Gallen, Switzerland, 19 January...
-
Jan 18, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 18 January 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global...
-
Jan 18, 2022
CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd. MELBOURNE, Australia and ST. GALLEN, Switzerland. CSL Behring AG, Berne,...
-
Jan 18, 2022Ad hoc release pursuant to Art. 53 LR, Switzerland
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender...